Search

Nitisinone

It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku. [L53253, L53258]

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

Nipocalimab

[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … [L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion.

Rolapitant

By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

Dicoumarol

In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

Bendazac

Bendazac is an oxyacetic acid [A39863, A39869]. … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.

Erdafitinib

[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

Tividenofusp alfa

Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099

Flurandrenolide

(From Martindale, The Extra Pharmacopoeia, 30th ed, p733) … A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive.

Carisoprodol

This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications